Integra LifeSciences Holdings Corporation (IART)
Integra LifeSciences Holdings Corporation Revenues: 196.18M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IART Revenues Rankings
| Overall | 59th percentile | 1780 of 4425 |
| Sector | 75th percentile | 116 of 470 in Healthcare |
| Industry | 76th percentile | 16 of 67 in Medical Instruments & Supplies |
IART Revenues Range, Past 5 Years
| Minimum | 134.77M | Jun 2007 |
| Maximum | 203.52M | Dec 2011 |
| Average | 173.64M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these IART related companies
IART News
Linda Littlejohns of Integra LifeSciences Assumes Presidency of American Association of Neuroscience Nurses
May 01, 6:00AM GlobeNewswire
May 01, 6:00AM GlobeNewswire
Listen to $IART Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3WVb
about 33 days ago by earningscast
about 33 days ago by earningscast
$IART filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3LPC
about 46 days ago by MarketBrief
about 46 days ago by MarketBrief
Integra LifeSciences to Host Its First Quarter 2012 Earnings Results Conference Call on April 26, 2012
Apr 06, 9:00AM GlobeNewswire
Apr 06, 9:00AM GlobeNewswire
Integra LifeSciences Announces Launch of New Jarit Take-Apart Laparoscopic Instruments
Mar 26, 6:46AM Benzinga
Mar 26, 6:46AM Benzinga
Integra LifeSciences Announces Launch of New Jarit(R) Take-Apart Laparoscopic Instruments
Mar 26, 6:00AM GlobeNewswire
Mar 26, 6:00AM GlobeNewswire
Integra LifeSciences Launches New Shoulder Arthroplasty Device in Italy and Sweden
Mar 22, 6:38AM Benzinga
Mar 22, 6:38AM Benzinga
Robbins Umeda LLP Announces an Investigation of Integra LifeSciences Holdings Corporation
Mar 19, 8:05AM Business Wire
Mar 19, 8:05AM Business Wire
Jefferies Raises Target On Integra LifeSciences (IART) to $37 After Q4 Results
Feb 24, 11:47AM Street Insider
Feb 24, 11:47AM Street Insider
Listen to $IART Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2Wh9
about 96 days ago by earningscast
about 96 days ago by earningscast
Integra Lifesciences Holdings (IART) Tops Q4 EPS by 9c; Guides FY12 EPS, Revs
Feb 23, 6:26AM Street Insider
Feb 23, 6:26AM Street Insider
Integra LifeSciences Reports Fourth Quarter and Full-Year 2011 Financial Results
Feb 23, 6:00AM GlobeNewswire
Feb 23, 6:00AM GlobeNewswire
$IART http://stks.co/2Mfs Failed at two month declining TrendLine after steep rally off lows.
about 107 days ago by TheEquitiesRoom
about 107 days ago by TheEquitiesRoom
$IART http://stks.co/26gV on watch list just sitting at gap with 34% ave full day volume
about 124 days ago by StockTiger
about 124 days ago by StockTiger
$IART Prelim. Q4 Below Street: EPS 65-70c, vs. cons. 79c, sales $202-$203M, vs. cons. $213M; got FDA warning letter on Plainsborough plant
about 145 days ago by Street_Insider
about 145 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IART | 35.59 | +0.30 | +0.85% | 948.60M |
| IAK | 29.77 | +0.26 | +0.88% | |
| IAG | 10.58 | -0.29 | -2.67% | 4.088B |
| IAF | 9.81 | +0.41 | +4.36% | |
| IAE | 14.79 | +0.14 | +0.96% | |
| IACI | 45.80 | +1.07 | +2.39% | 3.635B |
| HSNI | 39.67 | +0.43 | +1.10% | 2.272B |
| HSKA | 12.22 | +0.14 | +1.16% | 63.66M |
| HSII | 16.79 | +0.26 | +1.57% | 295.39M |
| HSFT | 13.06 | +0.17 | +1.32% | 404.23M |